**Name of Journal: *World Journal of Gastroenterology***

**Manuscript NO: 44516**

**Manuscript Type: ORIGINAL ARTICLE**

***Observational Study***

**Lethal-7-related polymorphisms are associated with susceptibility to and prognosis of gastric cancer**

Jia ZF *et al*. Let-7-related SNPs and gastric cancer

Zhi-Fang Jia, Dong-Hui Cao, Yan-Hua Wu, Mei-Shan Jin, Yu-Chen Pan, Xue-Yuan Cao, Jing Jiang

**Zhi-Fang Jia, Dong-Hui Cao, Yan-Hua Wu, Yu-Chen Pan, Jing Jiang,** Division of Clinical Research, the First Hospital of Jilin University, Changchun 130021, Jilin Province, China

**Mei-Shan Jin,** Division of Pathology, the First Hospital of Jilin University, Changchun 130021, Jilin Province, China

**Xue-Yuan Cao,** Department of Gastrointestinal Surgery, the First Hospital of Jilin University, Changchun 130021, Jilin Province, China

**ORCID number:** Zhi-Fang Jia (0000-0001-9838-1726); Dong-Hui Cao (0000-0002-6795-6395); Yan-Hua Wu (0000-0002-9920-3486); Yu-Chen Pan (0000-0002-6599-6430); Mei-Shan Jin (0000-0002-4776-0715); Xue-Yuan Cao (0000-0002-1982-1672); Jing Jiang (0000-0001-9714-9255).

**Author contributions:** Jiang J and Cao XY designed the research; Jia ZF, Cao DH, Wu YH, Pan YC, and Jin MS performed the research; Jia ZF and Jiang J analyzed the data; Jia ZF wrote the manuscript; Jiang J and Cao XY revised the manuscript.

**Supported by** National Natural Science Foundation of China, No. 81703293, 81673145, and No. 81373084; the Research Program of the Education Department of Jilin Province, No. 2016487; the Scientific and Technological Development Program of Jilin Province, No. 20180414055GH.

**Institutional review board statement:** This study was reviewed and approved the Ethics Committee of the First Hospital of Jilin University (Changchun, China).

**Informed consent statement:** All the subjects gave written informed consent to participate in the study before enrollment.

**Conflict-of-interest statement:** There are no conflicts of interest to report.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The items that should be included in reports of observational studies were checked and the file of STROBE statement was uploaded.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Corresponding author:** **Jing Jiang,** **PhD, Professor, Statistician,** Division of Clinical Research, the First Hospital of Jilin University, No. 71, Xinmin Street, Changchun 130021, Jilin Province, China. jiangjing19702000@jlu.edu.cn

**Telephone:** +86-431-81875408

**Fax:** +86-431-85654528

**Received:** December 4, 2018

**Peer-review started:** December 6, 2018

**First decision:** January 6, 2019

**Revised:** January 18, 2019

**Accepted:** January 26, 2019

**Article in press:** January 26, 2019

**Published online:** February 28, 2019

**Abstract**

***BACKGROUND***

The lethal-7 (*let-7*) family members and their targets are involved in the development and progression of tumors. *Let-7*-related polymorphisms have been reported to be associated with tumorigenesis and prognosis. In gastric cancer, however, the related studies are limited.

***AIM***

To investigate the role of *let-7*-related microRNA polymorphisms in the tumorigenesis and prognosis of gastric cancer in a Chinese population.

***METHODS***

A total of 898 gastric cancer patients and 992 tumor-free controls were recruited into this study from 2008 to 2013. Gastric cancer patients were followed periodically. Ten single nucleotide polymorphisms (SNPs) in the *let-7* gene region or their target mRNAs were genotyped using the MassARRAY system and their associations with the risk for or overall survival of gastric cancer were analyzed.

***RESULTS***

All the ten SNPs were in Hardy-Weinberg equilibrium. The C allele of the rs3811463 polymorphism in the 3’-untranslated region (UTR) of *LIN28A* was associated with a lower risk of gastric cancer [odds ratio (OR) = 0.74, 95% confidence interval (CI): 0.61-0.88, *P* = 0.001] after adjustment for age and *Helicobacter pylori* status. Seven hundred and thirty-five gastric cancer patients who had undergone radical tumorectomy were included in the survival analysis and their 5-year survival rate was 53.9% (95%CI: 50.1%-57.6%). The rs10889677 in the 3’-UTR of *IL23R* was corresponded to the prognosis of gastric cancer in a dose-response manner, in which the death risk increased by 25% [hazard ratio (HR) = 1.25, 95%CI: 1.04-1.45, *P* = 0.011] with each increase in the number of C alleles after controlling for other potential clinicopathological parameters.

***CONCLUSION***

The *let-7*-related polymorphism rs3811463 in *LIN28A* is associated with the susceptibility to gastric cancer and the *let-7*-related polymorphism rs10889677 in *IL23R* is associated with the prognosis of gastric cancer.

**Key words:** Gastric cancer; Risk; Susceptibility; Prognosis; Polymorphism; Lethal-7; LIN28A; IL23R

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip**: This study included a relatively large number of gastric cancer patients and tumor-free controls and explored the relationship of ten lethal-7 (*let-7*)-related single nucleotide polymorphisms with gastric carcinogenesis and prognosis. The results showed that the *LIN28A* rs3811463 polymorphism of the *let-7* target was associated with the development of gastric cancer and that the *IL23R* rs10889677 polymorphism was related to the overall survival of gastric cancer patients in a dose-dependent manner. This study adds evidence that polymorphisms represent a genetic factor that modifies the susceptibility to and prognosis of gastric cancer.

**Citation:** Jia ZF, Cao DH, Wu YH, Jin MS, Pan YC, Cao XY, Jiang J. Lethal-7-related polymorphisms are associated with susceptibility to and prognosis of gastric cancer. *World J Gastroenterol* 2019; 25(8): 1012-1023

**URL:** https://www.wjgnet.com/1007-9327/full/v25/i8/1012.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v25.i8.1012

**INTRODUCTION**

Gastric cancer (GC) is the fifth most common malignancy and the third leading cause of cancer-related death worldwide[[1](#_ENREF_1)]. It is estimated that there were 1 million new cases in 2018, and nearly half of the new cases were in China[[1](#_ENREF_1)]. Despite advances in the diagnosis and treatment of GC in recent decades, the prognosis for GC patients is still poor, especially in China, with the five-year survival rate of only approximately 30%[[2](#_ENREF_2)]. GC is a heterogeneous disease with distinct clinical, epidemiological, and molecular features and is thought to be a multifactorial disease influenced by environmental factors, microbial infection, and the host’s genetic background[[3](#_ENREF_3)]. Recently, increasing numbers of studies have identified that genetic variations, of which single nucleotide polymorphisms (SNPs) are the most common type, play an important role in the development and progression of tumors including GC[[4](#_ENREF_4),[5](#_ENREF_5)].

MicroRNAs (miRNAs) are endogenous small noncoding RNAs that bind the mRNAs of the target genes to inhibit their translation and/or induce their decay[[6](#_ENREF_6)]. It is estimated that more than 30% of human genes, involved in nearly all human physical and pathophysiological processes, are regulated by miRNAs[[7](#_ENREF_7)]. The miRNA lethal-7 (*let-7*) is the first miRNA identified in humans, and more than ten members of the *let-7* family have been identified, including *let-7a-1*, *let-7a-2*, *let-7a-3*, *let-7b*, *let-7c*, *let-7d*, *let-7e*, *let-7f-1*, *let-7f-2*, *let-7g*, and *let-7i*[[8](#_ENREF_8)]. *Let-7* often exhibits tumor-suppressor functions in tumorigenesis such as inhibiting proliferation, inducing apoptosis, and suppressing the invasion and metastasis of cancer cells[[8](#_ENREF_8)]. The *let-7* family members are often downregulated in several cancers, thus derepressing the oncogenic targets such as K-ras, LIN28A, c-Myc, and HMGA2[[9](#_ENREF_9)].

Previous studies have reported that miRNA-related SNPs could modulate the risk of tumors by altering the production of mature miRNAs or by affecting the binding affinity of miRNAs to their targets[[10](#_ENREF_10),[11](#_ENREF_11)]. Xie *et al*[[12](#_ENREF_12)] found that hepatocellular carcinoma patients carrying the C allele of rs10877887 in the promotor region of *let-7i* had a significantly increased death risk compared to patients with the TT genotype. The rs3811463 polymorphism is located in the 3’-untranslated region (UTR) of *LIN28A*, which is also near the target region of *let-7*. The C allele of rs3811463 could attenuate the *let-7*-induced repression of *LIN28A* mRNA, resulting in the increased production of LIN28A protein, which could in turn downregulate the level of mature *let-7* *via* an LIN28A/*let-7* double-negative feedback loop and alter breast cancer risk[[13](#_ENREF_13)]. In GC, however, the related studies are limited. This study was aimed to determine the role of *let-7* related SNPs in the susceptibility to and prognosis of GC.

**MATERIALS AND METHODS**

***Ethics statement***

This study was approved by the Ethics Committee of the First Hospital of Jilin University (2013-005). All participants provided written informed consent prior to joining the study.

***Subjects***

GC patients who were hospitalized for potential tumor resection were invited to participate in the study from July 2008 to December 2013 at the First Hospital of Jilin University. A total of 898 patients who had not undergone chemotherapy or radiotherapy before surgery were recruited to the study, and all of them were histologically diagnosed with GC. Demographical and clinicopathological information was collected. The tumor histological type was evaluated by the World Health Organization criteria, and clinical stages were classified according to the 7th edition of the TNM staging system of the Union for International Cancer Control/American Joint Committee on Cancer (2010) based on postoperative pathologic examination.

During the same period, tumor-free controls were recruited from the Physical Examination Center of the same hospital. Controls were frequency-matched with cases by sex and age (± 5 years), and 992 controls were included in the study.

***Follow-up***

GC patients were followed periodically after tumorectomy. Follow-ups were performed at 3 mo, 6 mo, and 1 year after surgery and annually afterwards. Information on general status and postoperative chemotherapy was collected during each follow-up. If the patients had died, the date of death and potential cause were recorded. Survival time was defined as the duration from the date of surgery to the date of death. If the patient was alive, survival time was defined as the duration from the date of surgery to the date of the last follow-up. If the patient was lost to follow-up, survival time was defined as the duration from the date of surgery to the date of the last successful interview. Survival time was right-censored in the latter two cases. Patients were excluded from the survival analysis if they were lost to follow-up at the first interview or if they died of postoperative complications such as uncontrollable bleeding during the perioperative period.

***Genotyping***

All subjects donated blood samples. Genomic DNA was isolated using blood genomic DNA extraction kits (Axygen Biosciences, Union City, CA, United States). Serum immunoglobulin G antibodies to *Helicobacter pylori* (*H. pylori*) were assessed using an enzyme-linked immunosorbent assay (Biohit, Helsinki, Finland). Titers higher than 30 enzyme immunounits were defined as positive for *H. pylori* according to the manufacturer’s instructions.

*Let-7*-related SNPs that were reportedly associated with cancer were selected and genotyped. Six SNPs are in the *let-7* gene region (rs13293512, rs562052, rs547008, rs1143770, rs629367, and rs10877887) and four SNPs are in the 3’-UTR of potential target genes of *let-7* (rs3811463 in *LIN28A*, rs10889677 in *IL23R*, rs7963551 in *RAD52*, and rs712 in *KRAS*). Genotypes were determined with the MassARRAY system (Sequenom Inc, CA, United States). The call rates were all greater than 95% (13 subjects for rs13293512, 10 for rs562052, 10 for rs547008, 26 for rs1143770, 2 for rs629367, 53 for rs10877887, 7 for rs10889677, 6 for rs7963551, and 31 for rs712, respectively, failed to genotype). Ten randomly selected samples were simultaneously genotyped twice, and the concordance rates were 100% for all loci.

***Statistical analysis***

Continuous variables are shown as the mean ± standard deviation (SD) and compared by Student’s *t*-test. Categorical variables are presented as frequencies with percentages and were compared with the *χ2* test or Fisher’s exact test when appropriate. Multivariate logistic regression analysis was employed to select the independent loci associated with the development of GC, and odds ratios (ORs) with their 95% confidence intervals (CIs) were calculated. Survival curves within each stratification of variables were plotted by the Kaplan-Meier method and compared by log-rank test. The multivariate Cox proportional hazard model was used to evaluate the prognostic role of polymorphisms, and hazard ratios (HRs) with their 95% CIs were calculated. All analyses were performed using SAS 9.2 software (SAS Institute Inc, United States). A two-tailed *P*-value < 0.05 indicated statistical signiﬁcance.

**RESULTS**

From 2008 to 2013, 898 GC cases and 992 tumor-free controls were enrolled in the study. Gender distribution was uniform between cases and controls (*P* = 0.886). The mean age of GC patients was 2 years older than that of the controls (61.1 years *vs* 59.2 years, respectively; *P* = 0.0002). Six hundred and three GC cases were positive for *H. pylori*, and the *H. pylori* positive rate (67.5%) was much higher in GC patients than in the control group (487/992 = 49.1%, *P* < 0.001) (Table 1).

***LIN28A rs3811463 is associated with gastric cancer risk***

Ten SNPs were genotyped in the study. All ten loci were in agreement with the Hardy-Weinberg equilibrium in the control group (*P* > 0.05). The distribution of the genotypes is presented in Table 2. The rs3811463 polymorphism in the 3’-UTR of *LIN28A* was distributed differently between GC cases and controls (*P* = 0.024). The proportions of T/C and C/C genotypes were lower in the GC group than in the control group (T/C: 22.6% *vs* 26.7%, respectively; C/C: 2.6% *vs* 3.8%, respectively). When compared to the population with the T/T genotype, individuals with the heterozygous T/C genotype had a decreased risk of GC (OR = 0.76, 95%CI: 0.61-0.94), and the risk was even lower for individuals with the C/C genotype (OR = 0.59, 95%CI: 0.34-1.01) after adjusting for age, gender, and *H. pylori* status. When the dominant model was used, the C allele (C/T + C/C) was associated with a reduced risk of GC (OR = 0.74, 95%CI: 0.60-0.91, *P* = 0.004). In stepwise logistic regression analysis, which included all loci, age, gender, and *H. pylori* status, rs3811463 was the only SNP site in the final model, and the risk of GC was lower by 26% with each increase of the number of C alleles (OR = 0.74, 95%CI: 0.61-0.88, *P* = 0.001), in addition to *H. pylori* status (OR = 2.20, 95%CI: 1.81-2.67, *P* < 0.001) and age (>65 years *vs* ≤65 years, OR = 1.31, 95%CI: 1.07-1.61, *P* = 0.010) (Table 3). The other nine SNPs, however, were not associated with GC risk.

***IL23R rs10889677 variant genotype predicts overall survival of gastric cancer***

Given the prognostic value of surgical tumorectomy, survival analysis was performed in patients who had undergone radical tumorectomy (Figure 1). Among the 898 GC cases included in this study, 143 were excluded for one of the following reasons: (1) distant metastasis; (2) not receiving curative tumorectomy; or (3) positive surgical margins. Of the remaining 755 patients, 5 were lost to follow-up at the first interview, and 15 died of postoperative complications within one month of surgery. These 20 patients were also excluded from the survival analysis. Thus, 735 patients were included in the final survival analysis (Figure 1). The median follow-up time until September 2017 for these 735 patients was 59.8 mo. During the follow-up period, 334 patients (45.4%) died, 383 (52.1%) survived, and 18 (2.4%) were lost to follow-up. The 5-year survival rate was 53.9% (95% CI 50.1%-57.6%) and the median survival time was estimated to be 77.7 mo.

We tested the association between SNP genotypes and the overall survival of GC patients with radical resection. We observed that patients with different rs10889677 genotypes had different survival curves (log-rank *P* = 0.049, Figure 2). More precisely, patients had worse survival with each increase in the number of C alleles of rs10889677. By the end of the study, 41.7% of patients with no rs10889677 C allele (A/A genotype) had died, while 48.5% of patients with one C allele (A/C genotype) and 56.6% of patients with two C alleles (C/C genotype) had died (Table 4). The five-year survival rate for A/A genotype patients was 57.7%, which was higher than that of patients with the A/C genotype (50.3%) or C/C genotype (46.0%). We further transformed the rs10889677 genotypes to a quantifiable trait (the number of C alleles) and observed that the death HR increased by 23% with each additional C allele (HR = 1.23, 95%CI: 1.04-1.45, *P* = 0.015). The other nine SNP loci were not significantly associated with the overall survival of GC patients (Table 4).

Age (*P* < 0.001), tumor differentiation level (*P* = 0.010), depth of tumor invasion (T stage, *P* < 0.001), local lymph node metastasis (N stage, *P* < 0.001), TNM stage (*P* < 0.001), lymphovascular invasion (*P* < 0.001), and neural invasion (*P* < 0.001) were associated with the long-term survival of GC patients in univariate survival analysis (Table 5). Postoperative chemotherapy was marginally related to the outcome (*P* = 0.054). *H. pylori* status, which was previously reported to be related to GC prognosis[[14](#_ENREF_14)], was not associated with the long-term OS in our study (*P* = 0.364, Table 5).

Further multivariate analysis showed that the rs10889677 polymorphism was an independent prognostic predictor and that the death HR increased by 23% with each increase in the number of C alleles (HR = 1.25, 95%CI: 1.04-1.45, *P* = 0.012) (Table 6). In addition, old age (>65 years, HR = 1.39, 95%CI: 1.10-1.75), high TNM stage [stage II (HR = 3.49, 95%CI: 1.88-6.48) or III (HR = 11.12, 95%CI: 6.0-20.61)], and positive lymphovascular invasion (HR = 1.89, 95%CI: 1.32-2.72) were also independently associated with decreased long-term survival. Additionally, chemotherapy after radical tumorectomy reduced the death hazard (HR = 0.75, 95%CI: 0.59-0.96, *P* = 0.021) (Table 6).

**DISCUSSION**

The *let-7* family members play an important role in several hallmarks of cancer, including repressing cellular proliferation, inducing cell apoptosis, suppressing aerobic glycolysis, inhibiting invasion and metastasis, and regulating tumor innate immune reactions by interacting with their targets[[8](#_ENREF_8)]. *Let-7*-related SNPs, which are located in the *let-7* gene region or in the target gene region, were reported to be associated with the development or prognosis of tumors. In this study, we explored the association of *let-7*-related SNPs with the susceptibility to and long-term overall survival of GC in a Chinese population. We observed that the rs3811463 in the 3’-UTR of *LIN28A* was associated with the susceptibility of GC and that rs10889677 in the 3’-UTR of *IL23R* was associated with the OS of resectable GC.

The *let-7* family and LIN28A compose a double-negative feedback loop. LIN28A represses *let-7* by inhibiting the biogenesis and inducing the degradation of the *let-7* family; meanwhile, *let-7* inhibits the expression and function of LIN28A *via* binding to complementary sites at the 3’-UTR of *LIN28A* mRNA[[8](#_ENREF_8)]. In contrast to the role of *let-7* in tumors, LIN28A promotes the proliferation of cancer cells and is related to the poor prognosis[[15](#_ENREF_15)]. Rs3811463 is located in the 3’-UTR of *LIN28A*, near the binding region of *let-7*. Chen *et al*[[13](#_ENREF_13)] reported that the C allele of rs3811463 corresponded to an increased risk of breast cancer by attenuating the *let-7*-induced LIN28A repression, which in turn downregulates the mature *let-7* *via* the LIN28A/*let-7* double-negative feedback loop. A subsequent study on oral cancer did not report any association between oral cancer risk and rs3811463 polymorphism in 384 cases and 731 controls[[16](#_ENREF_16)]. In our study, however, the C allele of rs3811463 was found to be associated with a reduced risk of GC. Moreover, this association demonstrated a dose-response manner in which the risk was lower with each increase in the number of C alleles compared to that of the patients without the C allele (*i.e*., genotype T/T). The online bioinformatics tool SNPinfo (<http://snpinfo.niehs.nih.gov/>) predicts that the change from T to C might make *LIN28A* gain the target of miR-490, which would reduce the level of *LIN28A*, thus associating with a lower risk of GC. However, further studies are needed to verify this hypothesis.

Interleukin-23 receptor (IL23R), a crucial subunit of the IL-23 receptor complex, is involved in innate and adaptive immune processes by interacting with IL-23, which plays a crucial role in many human diseases including autoimmune diseases and tumors[[17](#_ENREF_17),[18](#_ENREF_18)]. Because IL23R presents tumor-promoting effects, knockdown of *IL23R* restricts tumor growth and decreases cancer metastasis[[17](#_ENREF_17),[18](#_ENREF_18)]. The rs10889677 polymorphism, located in the 3’-UTR of the *IL23R* gene, has been reported to be associated with cancer risk, including the risk of breast cancer[[19](#_ENREF_19)], esophageal cancer[[20](#_ENREF_20)], bladder cancer[[21](#_ENREF_21)], ovarian cancer[[22](#_ENREF_22)], oral cancer[[23](#_ENREF_23)], and GC[[24](#_ENREF_24),[25](#_ENREF_25)]. The results of these studies, however, are controversial[[26](#_ENREF_26)]. In GC, Chen *et al* showed that the presence of the C allele of rs10889677 predicted lower GC risk (A/C: OR = 0.81, 95%CI: 0.66–0.99; C/C: OR = 0.47, 95%CI: 0.31–0.71)[[24](#_ENREF_24)], while another study by Dong *et al*[[25](#_ENREF_25)] observed an opposite relationship; the presence of the C allele increased the GC risk by 24% (Callele *vs* Aallele: OR = 1.24, 95%CI: 1.02–1.52). In our study, however, we did not find any significant association between rs10889677 and GC risk (*P* > 0.05). Nonetheless, we observed that the C allele was related to decreased survival of GC patients after curative tumorectomy in a dose-dependent manner, and the death HR increased by 25% (HR = 1.25, 95%CI: 1.05-1.49) with each increment in the number of the C alleles. This is the first study reporting that the rs10889677 of *IL23R* is related to the prognosis of GC, as most studies only focused on cancer susceptibility. Zwiers *et al*[[27](#_ENREF_27)] showed that the C allele of rs10889677 was corresponded to reduced *IL23R* levels possibly through the target gain of *let-7*. However, this could not explain what we had observed, and another unknown mechanism might be involved.

Studies have reported a significant correlation between SNPs in the *let-7* gene region and the susceptibility to or prognosis of malignant tumors, for example, rs629367 in *let-7a* and the risk of GC[[10](#_ENREF_10)], rs10877887 in *let-7i* and the risk of papillary thyroid carcinoma[[28](#_ENREF_28)] and survival of hepatocellular carcinoma[[12](#_ENREF_12)], and rs1143770 in *let-7a* and the overall survival and disease-free survival of surgically resected non-small cell lung cancer[[29](#_ENREF_29)]. Other studies, however, observed no such associations[[30](#_ENREF_30)]. In our study of a relatively large number of GC patients, we did not find that the six polymorphisms in the *let-7* gene region (rs13293512, rs562052, rs547008, rs1143770, rs629367, and rs10877887) were associated with the risk of development and the overall survival of GC. Several factors might contribute to the discrepancies among studies, such as different origins of the tumors studied and study populations from different ethnic groups. Therefore, more studies with a large sample size, including populations from different ethnic groups and tumors from multiple origins, are warranted in the future.

Two limitations should be noted in our study. First, although we observed that two SNPs were associated with GC, we could not verify the underlying mechanism for these associations because of our study design. Second, GC patients and controls from only one hospital were included in the study. The generalization of these results to other populations should be cautious because there has been no external validation. Therefore, more studies are needed to verify the results.

In summary, this study provides evidence that polymorphisms represent a genetic factor that modifies the susceptibility to and prognosis of GC. Individuals carrying the C allele of rs3811463 in the 3’-UTR of *LIN28A* have a lower risk of GC, and GC patients with the C allele of rs10889677 in the 3’-UTR of *IL23R* have a shorter lifespan than patients without it.

**ARTICLE HIGHLIGHTS**

***Research background***

Gastric cancer (GC) is one of the most common malignancies worldwide. Despite the advances in diagnosis and treatment of GC in recent decades, prognosis of GC patients is still poor. It is of great importance to identify biomarkers that could be helpful in the improvement of screening of high-risk individuals, early diagnosis, and predicting outcome for the individualized therapy.

***Research motivation***

The microRNA lethal-7 **(***let-7*) often exhibits tumor-suppressor functions in tumorigenesis. Single nucleotide polymorphisms (SNPs) in the *let-7* gene region or *let-7* target genes have been reported to modulate the risk of several cancers including breast cancer and lung cancer. In GC, the related studies are limited

***Research objectives***

By including a relatively large number of GC patients, this study aimed to determine the role of *let-7*-related polymorphisms in GC in a Chinese population.

***Research methods***

From 2008 to 2013, 898 consecutive GC patients and 992 tumor-free controls were recruited into the study. GC patients were followed periodically to determine their prognosis. Ten SNPs in the *let-7* gene region or their target mRNAs were genotyped using MassArray system and the associations with the risk or overall survival of GC were analyzed.

***Research results***

Two SNPs in *let-7* target genes were associated with GC in a dose-dependent manner. Rs3811463 in the 3’-UTR of *LIN28A* was associated with lower risk of GC and the risk was reduced by 26% with each increase of the C allele of rs3811463. The rs10889677 in the 3’-UTR of *IL23R* was corresponded to the prognosis of GC, and the death risk increased by 25% with each increment of the C allele of rs10889677, after controlling for clinicopathological parameters.

***Research conclusions***

*Let-7-*related SNPs were related to GC. The rs3811463 in *LIN28A* is associated with the susceptibility to and rs10889677 in *IL23R* is associated with the prognosis of GC.

***Research perspectives***

Our research adds evidence that polymorphisms represent a genetic factor to modify the susceptibility to and prognosis of GC. The underlying mechanisms of the associations should be elucidated in future studies.

**REFERENCES**

1 **Bray F**, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; **68**: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]

2 **Zeng H**, Chen W, Zheng R, Zhang S, Ji JS, Zou X, Xia C, Sun K, Yang Z, Li H, Wang N, Han R, Liu S, Li H, Mu H, He Y, Xu Y, Fu Z, Zhou Y, Jiang J, Yang Y, Chen J, Wei K, Fan D, Wang J, Fu F, Zhao D, Song G, Chen J, Jiang C, Zhou X, Gu X, Jin F, Li Q, Li Y, Wu T, Yan C, Dong J, Hua Z, Baade P, Bray F, Jemal A, Yu XQ, He J. Changing cancer survival in China during 2003-15: A pooled analysis of 17 population-based cancer registries. *Lancet Glob Health* 2018; **6**: e555-e567 [PMID: 29653628 DOI: 10.1016/S2214-109X(18)30127-X]

3 **Karimi P**, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: Descriptive epidemiology, risk factors, screening, and prevention. *Cancer Epidemiol Biomarkers Prev* 2014; **23**: 700-713 [PMID: 24618998 DOI: 10.1158/1055-9965.EPI-13-1057]

4 **Stenholm L**, Stoehlmacher-Williams J, Al-Batran SE, Heussen N, Akin S, Pauligk C, Lehmann S, Senff T, Hofheinz RD, Ehninger G, Kramer M, Goekkurt E. Prognostic role of microRNA polymorphisms in advanced gastric cancer: A translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). *Ann Oncol* 2013; **24**: 2581-2588 [PMID: 23975664 DOI: 10.1093/annonc/mdt330]

5 **Espinosa-Parrilla Y**, Muñoz X, Bonet C, Garcia N, Venceslá A, Yiannakouris N, Naccarati A, Sieri S, Panico S, Huerta JM, Barricarte A, Menéndez V, Sánchez-Cantalejo E, Dorronsoro M, Brennan P, Duarte-Salles T, B As Bueno-de-Mesquita H, Weiderpass E, Lund E, Clavel-Chapelon F, Boutron-Ruault MC, Racine A, Numans ME, Tumino R, Canzian F, Campa D, Sund M, Johansson M, Ohlsson B, Lindkvist B, Overvad K, Tjønneland A, Palli D, Travis RC, Khaw KT, Wareham N, Boeing H, Nesi G, Riboli E, Gonzalez CA, Sala N. Genetic association of gastric cancer with miRNA clusters including the cancer-related genes MIR29, MIR25, MIR93 and MIR106: Results from the EPIC-EURGAST study. *Int J Cancer* 2014; **135**: 2065-2076 [PMID: 24643999 DOI: 10.1002/ijc.28850]

6 **Engels BM**, Hutvagner G. Principles and effects of microRNA-mediated post-transcriptional gene regulation. *Oncogene* 2006; **25**: 6163-6169 [PMID: 17028595 DOI: 10.1038/sj.onc.1209909]

7 **Dalmay T**, Edwards DR. MicroRNAs and the hallmarks of cancer. *Oncogene* 2006; **25**: 6170-6175 [PMID: 17028596 DOI: 10.1038/sj.onc.1209911]

8 **Wang T**, Wang G, Hao D, Liu X, Wang D, Ning N, Li X. Aberrant regulation of the LIN28A/LIN28B and let-7 loop in human malignant tumors and its effects on the hallmarks of cancer. *Mol Cancer* 2015; **14**: 125 [PMID: 26123544 DOI: 10.1186/s12943-015-0402-5]

9 **Sun X**, Liu J, Xu C, Tang SC, Ren H. The insights of Let-7 miRNAs in oncogenesis and stem cell potency. *J Cell Mol Med* 2016; **20**: 1779-1788 [PMID: 27097729 DOI: 10.1111/jcmm.12861]

10 **Xu Q**, Dong Q, He C, Liu W, Sun L, Liu J, Xing C, Li X, Wang B, Yuan Y. A new polymorphism biomarker rs629367 associated with increased risk and poor survival of gastric cancer in chinese by up-regulated miRNA-let-7a expression. *PLoS One* 2014; **9**: e95249 [PMID: 24760009 DOI: 10.1371/journal.pone.0095249]

11 **Jiang Y**, Qin Z, Hu Z, Guan X, Wang Y, He Y, Xue J, Liu X, Chen J, Dai J, Jin G, Ma H, Wang S, Shen H. Genetic variation in a hsa-let-7 binding site in RAD52 is associated with breast cancer susceptibility. *Carcinogenesis* 2013; **34**: 689-693 [PMID: 23188672 DOI: 10.1093/carcin/bgs373]

12 **Xie K**, Liu J, Zhu L, Liu Y, Pan Y, Wen J, Ma H, Zhai X, Hu Z. A potentially functional polymorphism in the promoter region of let-7 family is associated with survival of hepatocellular carcinoma. *Cancer Epidemiol* 2013; **37**: 998-1002 [PMID: 24103425 DOI: 10.1016/j.canep.2013.09.005]

13 **Chen AX**, Yu KD, Fan L, Li JY, Yang C, Huang AJ, Shao ZM. Germline genetic variants disturbing the Let-7/LIN28 double-negative feedback loop alter breast cancer susceptibility. *PLoS Genet* 2011; **7**: e1002259 [PMID: 21912531 DOI: 10.1371/journal.pgen.1002259]

14 **Tsai KF**, Liou JM, Chen MJ, Chen CC, Kuo SH, Lai IR, Yeh KH, Lin MT, Wang HP, Cheng AL, Lin JT, Shun CT, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Distinct Clinicopathological Features and Prognosis of Helicobacter pylori Negative Gastric Cancer. *PLoS One* 2017; **12**: e0170942 [PMID: 28152027 DOI: 10.1371/journal.pone.0170942]

15 **Xu C**, Shen J, Xie S, Jiang Z, Huang L, Wang L. Positive expression of Lin28 is correlated with poor survival in gastric carcinoma. *Med Oncol* 2013; **30**: 382 [PMID: 23292830 DOI: 10.1007/s12032-012-0382-x]

16 **Zhang Y**, Zhu L, Wang R, Miao L, Jiang H, Yuan H, Ma H, Chen N. Genetic variants in let-7/Lin28 modulate the risk of oral cavity cancer in a Chinese Han population. *Sci Rep* 2014; **4**: 7434 [PMID: 25503985 DOI: 10.1038/srep07434]

17 **Yan J**, Allen S, Vijayan D, Li XY, Harjunpää H, Takeda K, Liu J, Cua DJ, Smyth MJ, Teng MWL. Experimental Lung Metastases in Mice Are More Effectively Inhibited by Blockade of IL23R than IL23. *Cancer Immunol Res* 2018; **6**: 978-987 [PMID: 29921599 DOI: [10.1158/2326-6066.CIR-18-0011](https://doi.org/10.1158/2326-6066.CIR-18-0011)]

18 **Langowski JL**, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft M. IL-23 promotes tumour incidence and growth. *Nature* 2006; **442**: 461-465 [PMID: 16688182 DOI: 10.1038/nature04808]

19 **Zheng J**, Jiang L, Zhang L, Yang L, Deng J, You Y, Li N, Wu H, Li W, Lu J, Zhou Y. Functional genetic variations in the IL-23 receptor gene are associated with risk of breast, lung and nasopharyngeal cancer in Chinese populations. *Carcinogenesis* 2012; **33**: 2409-2416 [PMID: 23042301 DOI: 10.1093/carcin/bgs307]

20 **Ni B**, Chen S, Xie H, Ma H. Functional polymorphisms in interleukin-23 receptor and susceptibility to esophageal squamous cell carcinoma in Chinese population. *PLoS One* 2014; **9**: e89111 [PMID: 24586528 DOI: 10.1371/journal.pone.0089111]

21 **Tang T**, Xue H, Cui S, Gong Z, Fei Z, Cheng S, Gui C. Association of interleukin-23 receptor gene polymorphisms with risk of bladder cancer in Chinese. *Fam Cancer* 2014; **13**: 619-623 [PMID: 24861772 DOI: 10.1007/s10689-014-9731-6]

22 **Zhang Z**, Zhou B, Zhang J, Chen Y, Lai T, Yan L, Liang A, Li Y, Wang Y, Chen Y, Zhang L, Xi MR. Association of interleukin-23 receptor gene polymorphisms with risk of ovarian cancer. *Cancer Genet Cytogenet* 2010; **196**: 146-152 [PMID: 20082850 DOI: 10.1016/j.cancergencyto.2009.09.006]

23 **Chien MH**, Hsin CH, Chou LS, Chung TT, Lin CH, Weng MS, Chou MY, Chen MK, Yang SF. Interleukin-23 receptor polymorphism as a risk factor for oral cancer susceptibility. *Head Neck* 2012; **34**: 551-556 [PMID: 21717520 DOI: 10.1002/hed.21779]

24 **Chen B**, Zeng Z, Xu L, Wu X, Yu J, Xue L, Hao Y, Wang Y, Sung JJ, Chen M, Hu P. IL23R +2199A/C polymorphism is associated with decreased risk of certain subtypes of gastric cancer in Chinese: a case-control study. *Cancer Epidemiol* 2011; **35**: 165-169 [PMID: 20863779 DOI: 10.1016/j.canep.2010.08.006]

25 **Dong K**, Xu Y, Yang Q, Shi J, Jiang J, Chen Y, Song C, Wang K. Associations of Functional MicroRNA Binding Site Polymorphisms in IL23/Th17 Inflammatory Pathway Genes with Gastric Cancer Risk. *Mediators Inflamm* 2017; **2017**: 6974696 [PMID: 29118466 DOI: 10.1155/2017/6974696]

26 **Liu XH**, Dai ZM, Kang HF, Lin S, Ma XB, Wang M, Liu K, Dai C, Wang XJ, Dai ZJ. Association of IL-23R Polymorphisms (rs6682925, rs10889677, rs1884444) With Cancer Risk: A PRISMA-Compliant Meta-Analysis. *Medicine* (Baltimore) 2015; **94**: e2361 [PMID: 26717375 DOI: 10.1097/MD.0000000000002361]

27 **Zwiers A**, Kraal L, van de Pouw Kraan TC, Wurdinger T, Bouma G, Kraal G. Cutting edge: A variant of the IL-23R gene associated with inflammatory bowel disease induces loss of microRNA regulation and enhanced protein production. *J Immunol* 2012; **188**: 1573-1577 [PMID: 22262659 DOI: 10.4049/jimmunol.1101494]

28 **Wang Y**, Wei T, Xiong J, Chen P, Wang X, Zhang L, Gao L, Zhu J. Association Between Genetic Polymorphisms in the Promoter Regions of Let-7 and Risk of Papillary Thyroid Carcinoma: A Case-Control Study. *Medicine* (Baltimore) 2015; **94**: e1879 [PMID: 26512603 DOI: 10.1097/MD.0000000000001879]


29 **Shin KM**, Jung DK, Hong MJ, Kang HJ, Lee WK, Yoo SS, Lee SY, Cha SI, Lee J, Kim CH, Seok Y, Cho S, Son JW, Lee EB, Jheon S, Kim YT, Park JY. The pri-let-7a-2 rs1143770C>T is associated with prognosis of surgically resected non-small cell lung cancer. *Gene* 2016; **577**: 148-152 [PMID: 26625972 DOI: 10.1016/j.gene.2015.11.036]

30 **Huang F**, Hu LM, Liu JB, Zhang YX, Hu ZB. [Relationship between genetic polymorphism of promoter region let-7 and genetic susceptibility to hepatocellular carcinoma]. *Zhonghua Yu Fang Yi Xue Za Zhi* 2011; **45**: 1093-1098 [PMID: 22336344 DOI: 10.3760/cma.j.issn.0253-9624.2011.12.010]


**P-Reviewer:** Aoyagi K, Nardone G, Park WS **S-Editor:** Yan JP

**L-Editor:** Wang TQ **E-Editor:** Yin SY

**Specialty type:** Gastroenterology and hepatology   
**Country of origin:** China   
**Peer-review report classification**  
**Grade A (Excellent):** 0  
**Grade B (Very good):** B, B, B  
**Grade C (Good):** 0  
**Grade D (Fair):** 0 **Grade E (Poor):** 0



**Figure 1 The flow chart of patients included in the survival analysis.**

****

**Figure 2 Survival plot of gastric cancer patients stratified by rs10889677 genotypes.** Compared with the survival of patients with no C allele of rs10889677 (genotype A/A, blue line), patients with one C allele (genotype C/A, red line) exhibited a decreased survival rate and patients with two C alleles (genotype C/C, cyan line) exhibited the lowest survival rate.

**Table 1 General characteristics of subjects included in this study**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Cases** | **Controls** | ***P-*value** |
| *n* | 898 | 992 |  |
| Gender |  |  |  |
| Male | 649 (72.3) | 714 (72.0) | 0.886 |
| Female | 249 (27.7) | 278 (28.0) |  |
| Age (yr) | 61.1±11.4 | 59.2 ± 10.0 | <0.001 |
| ≤65 | 582 (64.8) | 703 (70.9) | 0.005 |
| >65 | 316 (35.2) | 289 (29.1) |  |
| *Helicobacter pylori* |  |  |  |
| Negative | 290 (32.5) | 505 (50.9) | <0.001 |
| Positive | 603 (67.5) | 487 (49.1) |  |

**Table 2 The genotype distribution between gastric cancer cases and controls**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Gene** | **SNP** | **Genotypes** | **Cases** | **Controls** | ***P*-valuea** | **OR (95% CI)b** |
| *let-7a-1* | rs13293512 | T/T | 270 (30.3) | 310 (31.5) | 0.593 | 1.00 |
|  |  | T/C | 442 (49.6) | 494 (50.2) |  | 1.03 (0.83-1.28) |
|  |  | C/C | 180 (20.2) | 181 (18.4) |  | 1.13 (0.86-1.48) |
| *let-7a-2* | rs562052 | G/G | 382 (43.0) | 439 (44.3) | 0.814 | 1.00 |
|  |  | G/A | 413 (46.5) | 446 (45.0) |  | 1.06 (0.87-1.29) |
|  |  | A/A | 94 (10.6) | 106 (10.7) |  | 0.96 (0.70-1.32) |
| *let-7a-2* | rs547008 | C/C | 529 (59.2) | 575 (58.3) | 0.875 | 1.00 |
|  |  | C/T | 321 (35.9) | 358 (36.3) |  | 0.96 (0.79-1.17) |
|  |  | T/T | 44 (4.9) | 53 (5.4) |  | 0.85 (0.56-1.30) |
| *let-7a-2* | rs1143770 | T/T | 255 (28.9) | 282 (28.7) | 0.262 | 1.00 |
|  |  | T/C | 456 (51.8) | 482 (49.0) |  | 1.04 (0.83-1.29) |
|  |  | C/C | 170 (19.3) | 219 (22.3) |  | 0.83 (0.64-1.09) |
| *let-7a-2* | rs629367 | A/A | 532 (59.2) | 597 (60.3) | 0.583 | 1.00 |
|  |  | A/C | 323 (36.0) | 355 (35.9) |  | 1.01 (0.83-1.22) |
|  |  | C/C | 43 (4.8) | 38 (3.8) |  | 1.21 (0.76-1.92) |
| *let-7i* | rs10877887 | T/T | 370 (42.3) | 406 (42.2) | 0.777 | 1.00 |
|  |  | T/C | 399 (45.6) | 449 (46.7) |  | 0.96 (0.78-1.17) |
|  |  | C/C | 106 (12.1) | 107 (11.1) |  | 1.04 (0.76-1.42) |
| *LIN28A* | rs3811463 | T/T | 672 (74.8) | 689 (69.5) | **0.024** | 1.00 |
|  |  | T/C | 203 (22.6) | 265 (26.7) |  | **0.76 (0.61-0.94)** |
|  |  | C/C | 23 (2.6) | 38 (3.8) |  | **0.59 (0.34-1.01)** |
|  | Dominant | T/T | 672 (74.8) | 689 (69.5) | **0.009** | 1.00 |
|  |  | T/C+C/C | 226 (25.2) | 303 (30.5) |  | **0.74 (0.60-0.91)** |
| *IL23R* | rs10889677 | A/A | 476 (53.2) | 545 (55.2) | 0.685 | 1.00 |
|  |  | A/C | 356 (39.8) | 375 (38.0) |  | 1.10 (0.91-1.34) |
|  |  | C/C | 63 (7.0) | 68 (6.9) |  | 1.07 (0.74-1.55) |
| *RAD52* | rs7963551 | T/T | 597 (66.6) | 672 (68.0) | 0.666 | 1.00 |
|  |  | T/G | 267 (29.8) | 287 (29.0) |  | 1.06 (0.87-1.31) |
|  |  | G/G | 32 (3.6) | 29 (2.9) |  | 1.18 (0.69-2.01) |
| *KRAS* | rs712 | G/G | 540 (61.0) | 589 (60.5) | 0.646 | 1.00 |
|  |  | G/T | 296 (33.4) | 339 (34.8) |  | 0.94 (0.77-1.15) |
|  |  | T/T | 49 (5.5) | 46 (4.7) |  | 1.14 (0.74-1.75) |

a*P* was computed using the *χ2* test; bORs with 95%CIs were computed using a logistic model after adjusting for age, gender, and *Helicobacter pylori* status. SNP: Single nucleotide polymorphism; ORs: Odds ratios; CIs: Confidence intervals.

**Table 3 Multivariate stepwise logistic regression analysis of gastric cancer risk**

|  |  |  |  |
| --- | --- | --- | --- |
| **Factor** | **OR** | **95%CI** | ***P-*value** |
| rs3811463 (each increase in C allele) | 0.74 | 0.61-0.88 | 0.001 |
| *Helicobacter pylori* (positive *vs* negative) | 2.20 | 1.81-2.67 | <0.001 |
| Age (>65 *vs* ≤65 yr) | 1.31 | 1.07-1.61 | 0.010 |

OR: Odds ratio; CI: Confidence interval.

**Table 4 Genotypes of single nucleotide polymorphisms and overall survival of gastric cancer patients**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **SNP** | **Genotype** | **Total** | **Death (%)** | **5-yr**  **survival rate** | **Median survival time** | ***P-*value*a*** |
| rs13293512 | T/T | 213 | 100 (46.9) | 51.6% | 85.2 | 0.508 |
|  | T/C | 370 | 172 (46.5) | 53.3% | 75.8 |  |
|  | C/C | 148 | 60 (40.5) | 59.0% | --b |  |
| rs562052 | G/G | 313 | 150 (47.9) | 51.5% | 76.2 | 0.253 |
|  | G/A | 337 | 141 (41.8) | 56.9% | --b |  |
|  | A/A | 77 | 40 (51.9) | 50.7% | 65.4 |  |
| rs547008 | C/C | 434 | 200 (46.1) | 53.0% | 85.2 | 0.148 |
|  | C/T | 264 | 112 (42.4) | 56.2% | --b |  |
|  | T/T | 34 | 21 (61.8) | 46.7% | 33.8 |  |
| rs1143770 | T/T | 215 | 98 (45.6) | 54.3% | --b | 0.535 |
|  | T/C | 370 | 164 (44.3) | 54.4% | --b |  |
|  | C/C | 138 | 68 (49.3) | 51.3% | 65.4 |  |
| rs629367 | A/A | 435 | 205 (47.1) | 52.8% | 75.8 | 0.834 |
|  | A/C | 264 | 113 (42.8) | 55.6% | --b |  |
|  | C/C | 36 | 16 (44.4) | 55.8% | 85.2 |  |
| rs10877887 | T/T | 301 | 147 (48.8) | 50.4% | 64.7 | 0.235 |
|  | T/C | 330 | 141 (42.7) | 57.2% | --b |  |
|  | C/C | 88 | 39 (44.3) | 53.7% | --b |  |
| rs3811463 | T/T | 555 | 251 (45.2) | 53.7% | 85.2 | 0.971 |
|  | T/C | 162 | 75 (46.3) | 54.9% | 77.7 |  |
|  | C/C | 18 | 8 (44.4) | 52.0% | --b |  |
| rs10889677 | A/A | 379 | 158 (41.7) | 57.7% | --b | **0.049** |
|  | A/C | 301 | 146 (48.5) | 50.3% | 65.4 |  |
|  | C/C | 53 | 30 (56.6) | 46.0% | 41.0 |  |
| rs7963551 | T/T | 508 | 236 (46.5) | 52.56% | 85.2 | 0.144 |
|  | T/G | 199 | 82 (41.2) | 59.35% | --b |  |
|  | G/G | 27 | 16 (59.3) | 38.22% | 41.3 |  |
| rs712 | G/G | 452 | 215 (47.6) | 51.51% | 73.7 | 0.227 |
|  | G/T | 235 | 95 (40.4) | 58.64% | --b |  |
|  | T/T | 36 | 17 (47.2) | 55.01% | 77.7 |  |

a*P* was computed by log-rank test; bMedian survival time could not be estimated as fewer than 50% of patients died.

**Table 5 Associations between clinical factors and overall survival of gastric cancer patients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variable** | **Classification** | **Na** | **Death (%)** | **5-year survival (%)** | ***P-*value*b*** |
| Age (yr) | ≤65 | 494 | 197 (39.9) | 59.7 (55.0-64.0) | <0.001 |
|  | >65 | 241 | 137 (56.8) | 42.3 (35.6-48.8) |  |
| Gender | Female | 195 | 82 (42.1) | 56.8 (49.2-63.7) | 0.261 |
|  | Male | 540 | 252 (46.7) | 52.9 (48.4-57.2) |  |
| Differentiation | Poor | 508 | 241 (47.4) | 50.9 (46.2-55.3) | 0.010 |
|  | Moderate and high | 209 | 85 (40.7) | 61.6 (54.4-68.0) |  |
| WHO type | Tubular adenocarcinoma | 614 | 275 (44.8) | 54.8 (50.6-58.8) | 0.205 |
|  | Signet ring cell | 72 | 32 (44.4) | 52.8 (39.8-64.2) |  |
|  | Other | 45 | 25 (55.6) | 44.5 (29.2-58.6) |  |
| T stage | T1 | 100 | 13 (13.0) | 85.8 (76.5-91.6) | <0.001 |
|  | T2 | 102 | 16 (15.7) | 84.4 (74.8-90.6) |  |
|  | T3 | 423 | 220 (52.0) | 48.1 (43.1-52.9) |  |
|  | T4 | 103 | 78 (75.7) | 17.4 (9.2-27.8) |  |
| N stage | N0 | 219 | 38 (17.4) | 84.2 (78.4-88.5) | <0.001 |
|  | N1 | 184 | 63 (34.2) | 66.0 (58.2-72.6) |  |
|  | N2 | 150 | 87 (58.0) | 38.7 (30.3-47.1) |  |
|  | N3 | 175 | 139 (79.4) | 17.3 (11.7-23.9) |  |
| TNM | I | 137 | 12 (8.8) | 90.6 (83.9-94.6) | <0.001 |
|  | II | 278 | 92 (33.1) | 68.3 (62.1-73.6) |  |
|  | III | 313 | 223 (71.2) | 25.8 (20.7-31.2) |  |
| Lymphovascular invasion | Negative | 213 | 38 (17.8) | 83.0 (77.0-87.6) | <0.001 |
|  | Positive | 511 | 287 (56.2) | 42.6 (38.1-47.0) |  |
| Neural invasion | Negative | 328 | 100 (30.5) | 70.2 (64.6-75.0) | <0.001 |
|  | Positive | 396 | 225 (56.8) | 41.1 (36.0-46.2) |  |
| Chemotherapy | No | 488 | 218 (44.7) | 54.8 (50.0-59.3) | 0.054 |
|  | FOLFOX-4 | 136 | 63 (46.3) | 52.1 (43.2-60.3) |  |
|  | XELOX | 73 | 28 (38.4) | 61.7 (49.1-72.0) |  |
|  | Other | 38 | 25 (65.8) | 34.0 (19.1-49.4) |  |
| *Helicobacter pylori* | Negative | 228 | 109 (47.8) | 49.8 (42.7-56.4) | 0.364 |
|  | Positive | 503 | 222 (44.1) | 56.1 (51.4-60.4) |  |

aSome of the variables have missing values (The missing number was 4 for the variable of WHO type, 18 for differentiation, 7 for T stage, 7 for N stage, 7 for TNM stage, 11 for lymphovascular invasion, 11 for neural invasion, and 4 for *Helicobacter pylori*, respectively); b*P* was computed by log-rank test.

**Table 6 Multivariate Cox regression analysis of gastric cancer survival**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variable** | **Comparison** | **HR** | **95%CI** | ***P-*value** |
| rs10889677 | each increase in C allele | 1.25 | 1.05-1.49 | 0.012 |
| Age (yr) | >65 *vs* ≤ 65 | 1.39 | 1.10-1.75 | 0.005 |
| TNM stage | II *vs* I | 3.49 | 1.88-6.48 | <0.001 |
|  | III *vs* I | 11.12 | 6.00-20.61 | <0.001 |
| Lymphovascular invasion | Positive *vs* Negative | 1.89 | 1.32-2.72 | 0.001 |
| Chemotherapy | Yes *vs* No | 0.74 | 0.59-0.95 | 0.016 |

HR: Hazard ratio; CI: Confidence interval.